|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
ARCA biopharma Release: GencaroTM Demonstrated 74% Risk Reduction for New Onset Atrial Fibrillation in Heart Failure Patients with Genotype Believed to be Found in Nearly 50% of Population
11/16/2011 10:18:11 AM
BROOMFIELD, Colo.--(BUSINESS WIRE)--ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for atrial fibrillation and other cardiovascular diseases, today announced results of analyses of atrial fibrillation and pharmacogenetic data from the BEST trial, a previously conducted Phase 3 heart failure trial involving Gencaro in 2,708 advanced heart failure patients. Pursuant to their analysis, researchers concluded that Gencaro substantially decreased the risk of new onset atrial fibrillation in a large moderate-to-severe heart failure population, with a risk reduction of 41%. Furthermore, the researchers concluded that patients with a specific genotype (homozygous arginine at beta-1 389) had a 74% risk reduction for new onset atrial fibrillation. Based on a DNA sub-study in the BEST trial, ARCA believes approximately 50% of U.S. population has this specific genotype.
|
|
|
|
|
|
|
|
|
|
|